Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5847934 | 0.92 | GAA (0.39) | GAAMAPTTSHRMAPK1HTT | |
| SCHEMBL21706818 | 0.86 | GAA (0.36) | GAAMAPTTSHRMAPK1HTT | |
| SCHEMBL3842911 | 0.86 | GAA (0.38) | GAAMAPTTSHRMAPK1HTT | |
| SCHEMBL6426022 | 0.83 | GAA (0.48) | GAAMAPTTSHRMAPK1HTT | |
| SCHEMBL27482062 | 0.83 | TYR (0.41) | GAAMAPTTSHRMAPK1HTT | |
| SCHEMBL3844314 | 0.82 | TAAR1 (0.55) | HTR1DTAAR1ADRA1A | |
| SCHEMBL18533063 | 0.82 | ANPEP (0.39) | GAAMAPTTSHRMAPK1HTT | |
| SCHEMBL3841013 | 0.81 | TYR (0.47) | HTR1DTAAR1MAPTTSHRMAPK1 | |
| SCHEMBL3842146 | 0.81 | HTR2A (0.44) | HTR1DTAAR1HTT | |
| SCHEMBL2100738 | 0.81 | HTR2A (0.44) | HTR1DTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222054-A1 | PH SWITCHABLE REAGENTS AND METHODS FOR THEIR USE | IMPOSSIBLE FOODS INC (US) | 2016-08-04 | — | — | US | disclosed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-7420053-B2 | 2-imino-1,3-thiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2008-09-02 | — | — | US | disclosed |
| EP-1375489-B1 | MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE | SHIONOGI & CO (JP) | 2008-08-20 | — | — | EP | disclosed |
| EP-1219612-B1 | 2-IMINO-1,3-THIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20070088020-A1 | 2-imino-1,3-thiazine derivatives | HANASAKI KOJI | 2007-04-19 | — | — | US | disclosed |
| US-7183275-B2 | 2-imino-1,3-thiazine derivatives | SHIONOGI CO., LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-6916806-B2 | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO., LTD. (JP) | 2005-07-12 | — | — | US | disclosed |
| US-20050124617-A1 | 2-Imino-1,3-thiazine derivatives | HANASAKI KOJI (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-6818640-B1 | BIND SELECTIVELY TO CANNABINOID 2 RECEPTOR; ANTIINFLAMMATORY AGENTS | SHIONOGI & CO., LTD. (JP) | 2004-11-16 | — | — | US | disclosed |
| US-20040116326-A1 | Medicinal composition containing 1,3-thiazine derivative | SHIONOGI & CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1375489-A1 | MEDICINAL COMPOSITION CONTAINING 1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-1219612-A1 | 2-IMINO-1,3-THIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | HTR1D 170/4885TAAR1 173/4885GAA 4063/4885 |
| US-20160222054-A1 | PH SWITCHABLE REAGENTS AND METHODS FOR THEIR USE | PHPT1, CA6, HMBS | HTR1D 3755/4885TAAR1 2926/4885GAA 68/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | HTR1D 199/4885TAAR1 203/4885GAA 3645/4885 |
| US-20050124617-A1 | 2-Imino-1,3-thiazine derivatives | CNR2, CNR1, HTR2C | HTR1D 7/4885TAAR1 99/4885GAA 4768/4885 |
| US-20070088020-A1 | 2-imino-1,3-thiazine derivatives | CNR2, CNR1, HTR2C | HTR1D 7/4885TAAR1 99/4885GAA 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.